Our President and Chief Scientific Officer, Dr. Rachel Liberatore, attended the BIO International Convention in Boston last month. The event was a success, providing RenBio with valuable networking opportunities. Our revolutionary MYO Technology™ platform received a fervent response.

Dr. Liberatore had a great week engaging with a diverse array of potential collaborators and industry experts. The conference offered an ideal environment for establishing potential partnerships that will drive RenBio’s innovative initiatives forward.

RenBio remains focused on forging strategic collaborations and partnerships to accelerate the development and commercialization of MYO Technology™. We aim to build upon the momentum gained at BIO 2023 to advance our mission of revolutionizing DNA-based antibody and therapeutic protein delivery.

If you want to learn more about the clinical applications of our platform, here you will find every information.